Lipella Pharmaceuticals Inc
NASDAQ:LIPO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
L
|
Lipella Pharmaceuticals Inc
NASDAQ:LIPO
|
US |
|
C
|
CASI Pharmaceuticals Inc
NASDAQ:CASI
|
US |
|
Samick Musical Instruments Co Ltd
KRX:002450
|
KR |
|
L
|
Lakhotia Polyesters (India) Ltd
BSE:535387
|
IN |
|
Ziff Davis Inc
NASDAQ:ZD
|
US |
|
Daelim B&Co Co Ltd
KRX:005750
|
KR |
|
Ora Gold Ltd
ASX:OAU
|
AU |
|
E
|
ERG SA
WSE:ERG
|
PL |
|
Gauzy Ltd
NASDAQ:GAUZ
|
IL |
|
N
|
NTT System SA
WSE:NTT
|
PL |
|
Gujarat State Fertilizers & Chemicals Ltd
BSE:500690
|
IN |
|
United States Cellular Corp
NYSE:USM
|
US |
Lipella Pharmaceuticals Inc
Lipella Pharmaceuticals, Inc. develops and commercializes lipid-based therapies for common bladder syndromes. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 4 full-time employees. The company went IPO on 2022-12-20. The firm is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. Its lead product candidates include LP-10 and LP-310. LP-10 is its proprietary formulation of tacrolimus and is optimized for local delivery to the urinary bladder. LP-310, another proprietary formulation of tacrolimus, is optimized for delivery to the oral mucosa (the tissue lining the walls inside the mouth) and tongue surface. The company is developing LP-310 for the treatment of oral lichen planus (OLP), a chronic inflammatory condition affecting the mucous membranes inside the mouth. The company has developed a proprietary technology, referred to as its Platform, which is optimized for local hydrophobic drug delivery to body cavities having endothelial surfaces. Its Platform includes proprietary drug delivery technologies optimized for use with epithelial tissues.
Lipella Pharmaceuticals, Inc. develops and commercializes lipid-based therapies for common bladder syndromes. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 4 full-time employees. The company went IPO on 2022-12-20. The firm is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. Its lead product candidates include LP-10 and LP-310. LP-10 is its proprietary formulation of tacrolimus and is optimized for local delivery to the urinary bladder. LP-310, another proprietary formulation of tacrolimus, is optimized for delivery to the oral mucosa (the tissue lining the walls inside the mouth) and tongue surface. The company is developing LP-310 for the treatment of oral lichen planus (OLP), a chronic inflammatory condition affecting the mucous membranes inside the mouth. The company has developed a proprietary technology, referred to as its Platform, which is optimized for local hydrophobic drug delivery to body cavities having endothelial surfaces. Its Platform includes proprietary drug delivery technologies optimized for use with epithelial tissues.
